RESUMEN
【Objective】 To investigate scalp acupuncture’s protective effect on brain neurons and its effect on motor function in ischemic stroke rats and the possible mechanisms. 【Methods】 The rat model of ischemic stroke was prepared by the modified Longa suture method； the rats were randomly divided into model group， scalp acupuncture treatment group， inhibitor group， scalp acupuncture treatment + inhibitor group， and sham operation group. After a series of interventions， we evaluated the neurological， behavioral and motor functions of rats in each group after the treatment was over. TTC staining was used to detect cerebral infarction area. Neuron morphology was observed by Nissl staining. qPCR and Western blotting were used to detect the mRNA and protein expression levels of genes related to phosphatidyl inositol-3-kinase （PI3K）/serine-threonine protein kinase （AKt） pathway in the ischemic brain tissue of the rats. 【Results】 In the inhibitor group， the model group， the scalp acupuncture treatment group， and the scalp acupuncture treatment+inhibitor group， the neurological impairment and motor function score gradually decreased， the escape latency gradually shortened， the target quadrant residence time prolonged， the proportion of cerebral infarction area decreased， the number of Nissl bodies increased， the relative expressions of PI3K and AKt mRNA and protein increased （P<0.05）， and the neuronal morphology improved. 【Conclusion】 Scalp acupuncture can protect cerebral neurons of rats with ischemic stroke and enhance their motor function. The mechanism may be related to the regulation of PI3K/AKt signaling pathway.
RESUMEN
Objective:To evaluate the effect of Jianpi-Yishen-Tongluo capsules combined with candesartan cilexetil in the treatment of diabetic nephropathy (DN). Methods:According to the random table method, 82 patients who met the inclusion criteria in our hospital from January 2015 to December 2018 were divided into two groups, 41 in each group. The control group was treated with candesartan cilexetil, while the research group was treated with Jianpi-Yishen-Tongluo capsules based on the control group. Both groups were treated for 1 month. Then, the 24-hour urinary protein quantity (24 hPro) in urine, serum creatinine (SCr), blood urea nitrogen (BUN) were measured by automatic biochemical analyzer. The serum levels of visfatin (VF), glycosylated hemoglobin (HbAlc), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) were measured by ELISA. The adverse reaction during the treatment was observed and the clinical effect was evaluated. Results:The total effective rate of the research group was 97.6% (40/41), and 85.4% (35/41) of the control group, the difference between the two groups was statistically significant ( χ2=3.905, P=0.048). After the treatment, the 24 hPro (64.35 ± 6.39 mg vs. 96.32 ± 8.74 mg, t=18.908) in urine, SCr (86.84 ± 9.30 μmol/L vs. 124.34 ± 13.11 μmol/L, t=14.939), BUN (5.41 ± 0.59 mmol/L vs. 7.58 ± 0.71 mmol/L, t=15.052) in the research group were significantly lower than those of the control group ( P<0.01). The levels of VF and HbAlc in the research group were significantly lower than those of the control group ( t values were 10.595 and 13.140, respectively, all Ps<0.01), the serum levels of IL-6 and TNF-α were significantly lower than those of the control group ( t values were 10.071 and 6.969, respectively, all Ps<0.01). During the treatment, the incidence of adverse reactions was 12.2% (5/41) in the control group and 4.9% (2/41) in the research group, with no significant difference between the two groups ( χ2=1.406, P=0.236). Conclusions:The Jianpi-Yishen-Tongluo capsules combined with candesartan cilexetil can improve the renal function of DN patients, reduce the inflammatory reaction and improve the clinical effect.